 Notes from the East
Woods musings on opportunities in the life science
marketplace
September 2008
|
|
|
|
Greetings!
|
This month we take a lesson from colorful mushrooms that show how being different is a good thing. Please have a read and feel free to let me know what you think. Thanks.
Regards,
Paul Danis Founder and Principal
|
|
|
|
|
|
Differentiation and Colorful Fungi
|
I have finally
found out the great benefit of a cold and rainy August - mushrooms. I was walking through the woods the other day
and was treated to a brilliant display of fungus. What was most eye-catching, though, were the
incredible colors of the bright red, yellow, and purple orbs scattered about
the forest. It's really amazing how different one type is from the next. This differentiation in appearance is astonishing,
and in stark contrast to the situation in many life science markets. From automated workstations to protein Z,
products (and services) are usually far more alike than they are
different.
This sameness
causes many challenges to arise in the market both for producers as well as end
users of these offerings. Here are some
of the problems caused by a lack of differentiation. -
Competition is
inherently increased due to the overlap in features and messages about the
value. Coupled with the finite number of
opportunities, the battle to win customers is fierce.
-
Profitability goes
down as the value propositions become more similar - many fall back to price as
a differentiator
-
When products are
very similar to each other, the purchaser must spend additional time and effort sorting out the differences that matter to them. Thus, purchasing becomes more complex, and
sales cycles get longer. As an example,
there are over thirty different microarray scanners available from a dozen
companies. Needless to say it will take
some time to decide which one to actually purchase.
-
Ultimately your
product may not even get a chance to reach customers since its value is already
being supplied to the marketplace. Just
look at the recent case of Merck's cholesterol drug Vytorin where their press
release earlier this year stated, "...there was no significant difference between
treatment with ezetimibe/simvastatin [Vytorin] and simvastatin [current
product] alone on the pre-specified primary endpoint..." This public affirmation of the lack of
differentiation will cost Merck about $700M in sales.
A differentiated
product is a valuable thing since it usually leads to higher margins, faster
adoption, higher market share, and shorter selling cycles. So why is it so uncommon and how does one
achieve the coveted position of a unique product? Here are some ideas. -
It must first be
established that the product provides a good deal of value to the purchaser,
and that it does indeed solve a problem that matters to the target customers.
-
Next an honest
assessment of the current offerings needs to take place. Though a high level view is quick to
establish, open discussions with the target customers are critical to determine
the values being supplied. Use your
favorite visualization approach and map out the space covered by the various
offerings.
-
Look at your
product values in the context of the competition. If you are supplying value in an uninhabited
space (white or green) - congratulations.
If you are on top of or overlap with several other products you need to
make some decisions.
-
If you product is
already in the market, but struggling due to lack of differentiation, it could
be moved to a less cluttered segment.
Just look at how nicely the chromatic fungi all get along. The red ones are near the gravel, yellow ones
in the mossy area, and the purple ones in the dry leaves- a nice arrangement
where all can flourish without running in to each other.
-
Some other
options are to add or remove features (or services) to increase differentiation,
partner with a competitor and combine the offerings so both can benefit, or
lastly - obsolete the product and quit before you lose a lot of money. None of these solutions are cheap or easy,
but the alternative is to slug it out with similar products.
So strive to be
the red product in the midst of the yellow and purple - find a unique position
of value which will lead to higher profits, faster adoption and higher market
share.
|
Life Science Market Update
|
|
Index
|
August Value
|
Change YTD
|
Yearly High
|
Yearly Low
|
|
EC BioTools
|
798
|
3%
|
802
|
744
|
|
EC BigPharma
|
755
|
-1%
|
764
|
745
|
|
EC Biotech
|
711
|
3%
|
726
|
641
|
Many of the life science
indices currently available are a mixture of various types of companies. In
order to better assess the situation in the different segments, Eastwoods
Consulting has created these price-weighted indices for the sectors of large
pharmaceutical companies, biotech companies, and life science research tools
companies.
-
EC BioTools Index - A, ABI, ACCL, AFFX, BEC, BIO, BRKR,
CALP, DNEX, HBIO, HLCS, ILMN, IVGN (2:1 split in June), LMNX, PKI, QGEN, SIAL,
TMO, VARI, WAT
-
EC BigPharma Index - JNJ, PFE, GSK, NVS, SNY, MRK, ABT,
LLY, AZN, WYE, BMY, NVO, BAX, TEVA, SGP, RHHBY.PK
-
EB Biotech Index - DNA, AMGN, GENZ, BIIB, CEPH, GILD,
BMRN, AMLN, IDXX, SEPR, OSIP, PDLI, CPHD, ALKS, REGN, MEDX, THRX, HGSI, SGMO,
ENZN, NKTR
-
Prices are
taken at the close of each month.
|
|
| About Eastwoods Consulting
|
Eastwoods Consulting helps companies connect their technologies and products with the life science marketplace. By focusing on the most valuable opportunities, efficiency is increased, and profits grow.
|
Copyright © 2008, Eastwoods Consulting. This
publication may be freely redistributed in full or in part as long as full
attribution including our contact information and web address, are included. Eastwoods is a registered servicemark of Eastwoods Consultng.
|
|
|
|
|